ANT-GROUP
16.6.2022 05:03:07 CEST | Business Wire | Press release
Ant Group today announced the launch of Alipay+ Unified Payment. This major product upgrade provides a unified, scalable technical solution to help online and brick-and-mortar merchants collect money through all digital payment methods supported by Alipay+ in a more convenient and effective way.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220615006164/en/
Alipay+ offers a suite of innovative cross-border digital payments and marketing solutions, enabling merchants, especially small and medium-sized businesses, to better serve consumers worldwide. With this upgrade, Alipay+ Unified Payment further helps merchants directly reach over one billion consumers by making it easier for them to pay. Going forward, digital payment users in different countries can make cross-border payment with their local currencies wherever they see an Alipay+ sign, either online or offline, if the mobile payment methods they use adopt Alipay+ solutions.
After online merchants integrate Alipay+ Unified Payment, consumers will see an Alipay+ option when they make payments in their cashier pages. Cashiers will present users who choose to pay through Alipay+ recommended digital payment methods it supports based on their countries and payment preferences. Users can then proceed with paying using their preferred digital payment method. Brick-and-mortar merchants integrate Alipay+ Unified Payment by adopting a unified QR code scheme and scan-to-pay services, which can accept all digital payment methods enabled by Alipay+.
Alipay+ Unified Payment brings merchants highly efficient and cost-optimized digitalized cashier experiences. After one-time integration, merchants can accept all available digital payment methods, including existing methods and ones to be introduced by Alipay+ later on. Moreover, with innovative and digital-native technologies, Alipay+ can be integrated into merchants’ own systems with a simple technical adaption. Alipay+ Unified Payment also provides marketing services as part of its cashier solutions to help merchants expand the reach of targeted potential users.
Alipay+ Unified Payment began its pilot phase in May 2022. Merchants, including Buygogo, an e-commerce platform and Smile.one, one of the leading top-up services for online games and entertainment, have participated in the pilot program.
“We’re excited to launch Alipay+ Unified Payment, a one-stop solution integrating a wide range of digital payment methods. This upgrade helps merchants handle digital payments more conveniently and seamlessly, and greatly improves their operating efficiency,” said Cheng Guoming, General Manager of Alipay+ Global Partnership, Ant Group. “We are dedicated to leveraging our innovative products and technologies to better serve merchants around the world and facilitating even more cross-border business activities as the global economy recovers from the pandemic.”
About Alipay+
Alipay+ provides global cross-border digital payments and marketing solutions that enable global e-wallets and merchant partners, especially small and medium-sized businesses, to better serve their users and customers.
Alipay+ is introduced by Ant Group, the owner and operator of Alipay. As one of the world’s leading digital payment platforms, Alipay serves hundreds of millions of users by connecting them with merchants and partner financial institutions that offer inclusive financial services and digital daily life services.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220615006164/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom